Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the colon
• * 15 cm above anal verge
• * Stage III disease (any pT, N1-2, M0)
• No rectal cancer
• Must have undergone curative radical resection (R0 resection) within the past 6 weeks
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• WHO 0-1
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hepatic
• AST ≤ 5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• Renal
• Creatinine ≤ 1.5 times ULN
• Cardiovascular
• None of the following conditions within the past 6 months:
• * Myocardial infarction
• * Unstable angina
• * Symptomatic congestive heart failure
• * Serious uncontrolled cardiac arrhythmia
• * Cerebrovascular accident or transient ischemic attack
• * Deep vein thrombosis
• * Other significant thromboembolic event
• Pulmonary
• No pulmonary embolism within the past 6 months
• Gastrointestinal
• No active gastric or duodenal ulceration within the past year
• No gastrointestinal bleeding within the past year
• No partial or complete bowel obstruction
• No known chronic malabsorption
• No active inflammatory bowel disease or chronic diarrhea (more than 4 stools/day)
• Other
• Not pregnant or nursing
• Fertile patients must use effective contraception
• HIV negative
• No AIDS-related illness
• No prior hypersensitivity to fluorouracil, leucovorin calcium, celecoxib, other COX-2 inhibitors, NSAIDs, salicylates, or sulfonamides
• No other severe acute or chronic medical condition or laboratory abnormality that would preclude study participation, study drug administration, or study results interpretation
• No psychological, familial, sociological, or geographical condition that would preclude study compliance
• No concurrent active infection
• No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent sargramostim (GM-CSF) or molgramostim
• Chemotherapy
• Not specified
• Endocrine therapy
• No more than 4 weeks of concurrent orally/nasally inhaled steroids over a 6-month period
• * Concurrent mometasone (or fluticasone) allowed if patients require ≥ 4 weeks of inhaled steroid therapy
• At least 30 days since other prior steroids
• No concurrent hormonal therapy
• Radiotherapy
• No concurrent radiotherapy
• Surgery
• See Disease Characteristics
• No prior total colectomy or other major surgery that would result in substantial alteration in transit to absorption of oral medication
• Other
• More than 30 days since prior investigational medication
• No prior systemic anticancer treatment for colon cancer
• No concurrent prophylactic fluconazole
• No concurrent lithium
• No concurrent chronic\* use of full dose aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or cyclo-oxygenase-2 (COX-2) inhibitors
• * Aspirin at cardioprotective doses (i.e., 80 mg daily or equivalent) allowed
• No concurrent participation in any other clinical study
• No other concurrent experimental agents (e.g., other COX-2 inhibitors, matrix metalloproteinase inhibitors, inhibitors of the vascular endothelial growth factor/Flk-1 pathway, or inhibitors of the epidermal growth factor receptor pathway) NOTE: \*Chronic use is defined as a frequency of 7 consecutive days (1 week) for more than 3 weeks/year or more than 21 days throughout the year